Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma

被引:44
作者
Drance, SM
Crichton, A
Mills, RP
机构
[1] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada
[2] Foothills Prov Gen Hosp, Glaucoma Clin, Calgary, AB T2N 2T9, Canada
[3] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA
关键词
D O I
10.1016/S0002-9394(98)00019-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To compare the calculated mean ocular perfusion pressure at the end of 3 weeks' treatment with latanoprost 0.005% once daily or timolol 0.5% twice daily in normal-tension glaucoma patients. METHODS: In a three-center, double masked, randomized, crossover study, 36 patients were allocated to two treatment groups; one received 3 weeks each of placebo, latanoprost, placebo, and timolol, whereas the other group had placebo, timolol, placebo, and latanoprost. Intraocular pressure and resting systemic blood pressure were measured at 9 AM, 12 noon, and 4 PM. Ocular perfusion pressure was calculated for each time period as well as the mean of three values (daytime average). Systemic blood pressure and heart rate were also recorded at 30 minute intervals during the last 24 hours of each treatment period. RESULTS: The average daytime mean ocular perfusion pressure (mean +/- SEM) following latanoprost treatment was 53.2 +/- 1.4 mm Hg, an increase of 8% from the latanoprost run in period, compared with 50.9 +/- 1.1 mm Hg following timolol treatment, an increase of 2% from the timolol run-in period (P < .05, ANOVA). Timolol reduced the blood pressure. The difference in mean daytime and nighttime systolic blood pressure measurements as well as nighttime diastolic blood pressure was about 5 mm Hg between the latanoprost and timolol treatments. The daytime and nighttime heart rates were also slower during the timolol treatment. CONCLUSION: Because ocular perfusion pressure may be important in some glaucomatous patients, latanoprost appears to affect ocular per fusion pressure more favorably than timolol does in patients with normal-tension glaucoma. (C) 1998 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:585 / 592
页数:8
相关论文
共 17 条
[1]   Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol [J].
Alm, A ;
Stjernschantz, J ;
Widengard, I ;
Linden, C ;
Soderstrom, M ;
Nilsson, SE ;
Fristrom, B ;
Lindblom, B ;
Heijl, A ;
Gundersen, KG ;
Ehinger, B ;
Holmin, C ;
BengtssonStigmar, E ;
Aasved, H ;
Jangard, P ;
Ringvold, A ;
Vegge, T ;
Halseide, R ;
LundAndersen, H ;
Flesner, P ;
Thygesen, J ;
Airaksinen, J ;
Tuulonen, A .
OPHTHALMOLOGY, 1995, 102 (12) :1743-1752
[2]  
Bill A, 1978, GLAUCOMA CONCEPTIONS, P97
[3]   Latanoprost, a prostaglandin analog, for glaucoma therapy - Efficacy and safety after 1 year of treatment in 198 patients [J].
Camras, CB ;
Alm, A ;
Watson, P ;
Stjernschantz, J ;
Aasved, H ;
Jangard, P ;
LundAndersen, H ;
Flesner, P ;
Soderstrom, M ;
Ehinger, B ;
Holmin, C ;
BengtssonStigmar, E ;
Heijl, A ;
Gundersen, KG ;
Airaksinen, J ;
Tuulonen, A ;
Halseide, R ;
Lindblom, B ;
Ringvold, A ;
Vegge, T ;
Linden, C ;
Nilsson, SE ;
Fristrom, B ;
Widengard, I ;
Thygesen, J ;
Green, F ;
Valenzuela, F ;
Potts, M ;
Spencer, I ;
Coakes, R ;
Reynolds, P ;
Mills, B ;
Chatterjee, A ;
Nagasubramanian, S ;
Roxburgh, S ;
Sanders, R ;
Bailey, M ;
Whyte, IF ;
Vernon, S ;
Sloper, M ;
Murray, S ;
Davey, C ;
HickmanCasey, J ;
Longstaff, S ;
Currie, Z ;
Wishart, P ;
Austin, M ;
Birch, M ;
Elkington, A ;
Luff, A .
OPHTHALMOLOGY, 1996, 103 (11) :1916-1924
[4]   Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - A six-month, masked, multicenter trial in the United States [J].
Camras, CB ;
Cioffi, GA ;
VanBuskirk, EM ;
Fraser, J ;
Stewart, WC ;
Stewart, JA ;
Lustgarten, J ;
Schumer, RA ;
Podos, SM ;
Arroyo, M ;
Nitzberg, S ;
Ritch, R ;
Abundo, G ;
Caronia, R ;
Liebmann, J ;
Steinberger, D ;
Krupin, T ;
Rosenberg, LF ;
Ruderman, JM ;
Clarkson, K ;
Weinreb, RN ;
Ochabsi, R ;
Sherwood, M ;
Smith, MF ;
Stokes, DW ;
Zam, ZS ;
Wilensky, J ;
Hillman, D ;
Kaplan, B ;
Gates, V ;
Nail, C ;
Zimmerman, T ;
Fechtner, R ;
Fenton, R ;
Fenton, J ;
Higginbotham, EJ ;
Johnson, AT ;
PollackRundle, CJ ;
Weiss, E ;
Yablonski, ME ;
Tannenbaum, MH ;
Ibrahim, F ;
Ohia, E ;
Neely, D ;
Minckler, D ;
Heuer, D ;
Lee, P ;
Padea, M ;
Kaufman, PL ;
Heatley, GA .
OPHTHALMOLOGY, 1996, 103 (01) :138-147
[5]   AVOIDING UNSUSPECTED RESPIRATORY SIDE-EFFECTS OF TOPICAL TIMOLOL WITH CARDIOSELECTIVE OR SYMPATHOMIMETIC AGENTS [J].
DIGGORY, P ;
CASSELSBROWN, A ;
VAIL, A ;
ABBEY, LM ;
HILLMAN, JS .
LANCET, 1995, 345 (8965) :1604-1606
[6]   OCULAR BETA-BLOCKERS AND SYSTEMIC EFFECTS [J].
FRAUNFELDER, FT .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (06) :1073-1074
[7]   TOPICAL OPHTHALMIC BETA-ADRENERGIC-BLOCKADE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION [J].
FRISHMAN, WH ;
FUKSBRUMER, MS ;
TANNENBAUM, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (08) :795-803
[8]  
GRAHAM SL, 1995, OPHTHALMOLOGY, V102, P61
[9]   NOCTURNAL ARTERIAL-HYPOTENSION AND ITS ROLE IN OPTIC-NERVE HEAD AND OCULAR ISCHEMIC DISORDERS [J].
HAYREH, SS ;
ZIMMERMAN, MB ;
PODHAJSKY, P ;
ALWARD, WLM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 117 (05) :603-624
[10]   ADVERSE-EFFECTS EXPERIENCED BY PATIENTS TAKING TIMOLOL [J].
MCMAHON, CD ;
SHAFFER, RN ;
HOSKINS, HD ;
HETHERINGTON, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1979, 88 (04) :736-738